scholarly article | Q13442814 |
P819 | ADS bibcode | 2014PLoSO...990153W |
P356 | DOI | 10.1371/JOURNAL.PONE.0090153 |
P932 | PMC publication ID | 3940848 |
P698 | PubMed publication ID | 24595218 |
P5875 | ResearchGate publication ID | 260527228 |
P2093 | author name string | Huan Wang | |
Yu Fu | |||
Xiaohua Hou | |||
Wei Qian | |||
Jing Gong | |||
Wenfeng Wang | |||
Yanqin Long | |||
Xiaochao Fu | |||
P2860 | cites work | Prevalence of irritable bowel syndrome: a community survey | Q24535897 |
A systematic review and meta-analysis: probiotics in the treatment of irritable bowel syndrome | Q33409756 | ||
Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome | Q33421773 | ||
The efficacy of Lactobacillus reuteri ATCC 55730 in the treatment of patients with irritable bowel syndrome--a double blind, placebo-controlled, randomized study | Q33433775 | ||
A randomized controlled trial of a probiotic combination VSL# 3 and placebo in irritable bowel syndrome with bloating | Q33434046 | ||
Treatment of irritable bowel syndrome with probiotics. An etiopathogenic approach at last? | Q33443774 | ||
Probiotics and prebiotics in the management of irritable bowel syndrome: a review of recent clinical trials and systematic reviews | Q33451712 | ||
Effect of probiotic species on irritable bowel syndrome symptoms: A bring up to date meta-analysis | Q33457565 | ||
Probiotic treatment of irritable bowel syndrome in children | Q33730572 | ||
A controlled, double-blind, randomized study on the efficacy of Lactobacillus plantarum 299V in patients with irritable bowel syndrome | Q33955996 | ||
Probiotics: future directions | Q34274145 | ||
Epithelial cell proliferation arrest induced by lactate and acetate from Lactobacillus casei and Bifidobacterium breve | Q34706995 | ||
Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome | Q34731103 | ||
The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review | Q34906850 | ||
Postinfectious irritable bowel syndrome | Q34982123 | ||
AGA technical review on irritable bowel syndrome | Q35010302 | ||
Bifidobacterial surface-exopolysaccharide facilitates commensal-host interaction through immune modulation and pathogen protection. | Q35750853 | ||
Gastrointestinal microbiome signatures of pediatric patients with irritable bowel syndrome. | Q36160305 | ||
Preventive effect of glutamine on intestinal barrier dysfunction induced by severe trauma | Q36309080 | ||
Meta-analysis of probiotics for the treatment of irritable bowel syndrome | Q37156630 | ||
Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study | Q37417328 | ||
Bifidobacterium infantis 35624: a novel probiotic for the treatment of irritable bowel syndrome. | Q37444649 | ||
Th17: a new participant in gut dysfunction in mice infected with Trichinella spiralis | Q37452755 | ||
Review article: probiotics for the treatment of irritable bowel syndrome--focus on lactic acid bacteria. | Q37973803 | ||
VSL#3 improves symptoms in children with irritable bowel syndrome: a multicenter, randomized, placebo-controlled, double-blind, crossover study | Q39286213 | ||
A mixture ofEscherichia coli(DSM 17252) andEnterococcus faecalis(DSM 16440) for treatment of the irritable bowel syndrome - A randomized controlled trial with primary care physicians | Q56883300 | ||
Lactobacillus and bifidobacterium in irritable bowel syndrome: Symptom responses and relationship to cytokine profiles | Q59880418 | ||
Spectrophotometric assay for D-(-)-lactate in plasma | Q71136665 | ||
Intestinal adherent bacteria and bacterial translocation in breast-fed and formula-fed rats in relation to susceptibility to infection | Q73484608 | ||
Short-term sensitization of colon mechanoreceptors is associated with long-term hypersensitivity to colon distention in the mouse | Q80440416 | ||
Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome | Q84705462 | ||
Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome | Q39348241 | ||
A randomized controlled trial of a probiotic, VSL#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome | Q39396709 | ||
The prevalence, symptom characteristics, and impact of irritable bowel syndrome in an asian urban community | Q39684155 | ||
Gut microbiota is not modified by Randomized, Double-blind, Placebo-controlled Trial of VSL#3 in Diarrhea-predominant Irritable Bowel Syndrome | Q40306009 | ||
Tight junctions and the molecular basis for regulation of paracellular permeability | Q40373935 | ||
Diamine oxidase: an overview of historical, biochemical and functional aspects | Q40760854 | ||
D-lactate production and excretion in diarrheic calves | Q42162214 | ||
Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome | Q44520650 | ||
Lactobacillus paracasei normalizes muscle hypercontractility in a murine model of postinfective gut dysfunction | Q44802880 | ||
Impact of Bifidobacterium bifidum MIMBb75 on mouse intestinal microorganisms | Q46456070 | ||
An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. | Q48516420 | ||
Psychometric scores and persistence of irritable bowel after infectious diarrhoea. | Q51117034 | ||
Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. | Q53184076 | ||
Characteristics of intestinal lamina propria dendritic cells in a mouse model of postinfectious irritable bowel syndrome. | Q53201131 | ||
Carbohydrates and Lipids in Trichinella spiralis Larvae and Their Utilization In vitro | Q53780528 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | e90153 | |
P577 | publication date | 2014-03-03 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Are there any different effects of Bifidobacterium, Lactobacillus and Streptococcus on intestinal sensation, barrier function and intestinal immunity in PI-IBS mouse model? | |
P478 | volume | 9 |
Q47160578 | A Novel Prebiotic Blend Product Prevents Irritable Bowel Syndrome in Mice by Improving Gut Microbiota and Modulating Immune Response |
Q38376282 | Animal models of gastrointestinal and liver diseases. Animal models of visceral pain: pathophysiology, translational relevance, and challenges |
Q64065548 | Butyrate production in patients with end-stage renal disease |
Q28817192 | Can probiotics modulate human disease by impacting intestinal barrier function? |
Q55612911 | Dynamic changes in morphology, gene expression and microbiome in the jejunum of compensatory-growth rats induced by protein restriction. |
Q90136095 | Effect of mild moxibustion on intestinal microbiota and NLRP6 inflammasome signaling in rats with post-inflammatory irritable bowel syndrome |
Q40610748 | Effect of probiotic bacteria on phagocytosis and respiratory burst activity of blood polymorphonuclear leukocytes (PMNL) in mice infected with Trichinella spiralis. |
Q92318232 | Effects of probiotic supplementation on post-infectious irritable bowel syndrome in rodent model |
Q35586987 | Efficacy of combination therapy with probiotics and mosapride in patients with IBS without diarrhea: a randomized, double-blind, placebo-controlled, multicenter, phase II trial. |
Q55517435 | Fecal Microbiota Transplantation Is Effective in Relieving Visceral Hypersensitivity in a Postinfectious Model. |
Q36040649 | Fermented Yupingfeng polysaccharides enhance immunity by improving the foregut microflora and intestinal barrier in weaning rex rabbits |
Q42356646 | Gastrointestinal neuromuscular apparatus: An underestimated target of gut microbiota |
Q37289543 | Ginsenoside Rb1 protects the intestinal mucosal barrier following peritoneal air exposure |
Q28085584 | Gut microbiota as potential orchestrators of irritable bowel syndrome |
Q38815064 | Helminths and intestinal barrier function |
Q36355131 | Isomalto-oligosaccharides ameliorate visceral hyperalgesia with repair damage of ileal epithelial ultrastructure in rats. |
Q48313903 | Oral probiotic treatment of Lactobacillus rhamnosus Lcr35® prevents visceral hypersensitivity to a colonic inflammation and an acute psychological stress. |
Q58590765 | Pharmacological Activation of PXR and CAR Down-regulates Distinct Bile Acid-metabolizing Intestinal Bacteria and Alters Bile Acid Homeostasis |
Q40387665 | Piezo2: A Candidate Biomarker for Visceral Hypersensitivity in Irritable Bowel Syndrome? |
Q41087764 | Preinduction of heat shock protein 70 protects mice against post-infection irritable bowel syndrome via NF-κB and NOS/NO signaling pathways |
Q57465741 | Probiotic Clostridium butyricum Improves the Growth Performance, Immune Function, and Gut Microbiota of Weaning Rex Rabbits |
Q41643040 | Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. |
Q58693647 | Qi-Deficiency Related Increases in Disease Susceptibility Are Potentially Mediated by the Intestinal Microbiota |
Q57094367 | Seasonality of the gut microbiota of free-ranging white-faced capuchins in a tropical dry forest |
Q41985685 | Serum IL-17 and IL-6 increased accompany with TGF-β and IL-13 respectively in ulcerative colitis patients |
Q36340310 | Specific immunotherapy in combination with Clostridium butyricum inhibits allergic inflammation in the mouse intestine |
Q38645789 | Starring role of toll-like receptor-4 activation in the gut-liver axis |
Q51684544 | Study on the effects of microencapsulated Lactobacillus delbrueckii on the mouse intestinal flora. |
Q34151572 | The effect of peritoneal air exposure on intestinal mucosal barrier |
Q26739291 | The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments |
Q87356652 | Thrombospondin 1 Modulates Monocyte Properties to Suppress Intestinal Mucosal Inflammation |
Search more.